Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy

Juan M. Arriaga, Angela Greco, José Mordoh, Michele Bianchini

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kB activity. Despite being silenced, MTs can be reinduced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate. In fact, this induction contributes to the cytotoxicity of these agents, given that silencing of MTs by siRNAs reduces their growth-inhibitory activities. Zinc ions also potently enhanceMT expression and are cytotoxic to cancer cells. We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kB. Addition of zinc enhanced growth inhibition by OXA and 5- FU, and was also capable of resensitizing 5-FU-resistant cell lines to levels comparable with sensitive cell lines. This effect wasMTindependent because silencing MTs did not affect zinc cytotoxicity. In conclusion, we show that MT induction and zinc administration are novel strategies to sensitize colorectal cancer cells to presently utilized chemotherapeutic agents.

Original languageEnglish
Pages (from-to)1369-1381
Number of pages13
JournalMolecular Cancer Therapeutics
Volume13
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

oxaliplatin
Zinc
Colorectal Neoplasms
Drug Therapy
Fluorouracil
NF-kappa B
Metallothionein
Cell Line
trichostatin A
Histone Deacetylase Inhibitors
Butyric Acid
Growth
Fluorescent Dyes
Epigenomics
zinc thionein
Protein Isoforms
Molecular Weight
Ions
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. / Arriaga, Juan M.; Greco, Angela; Mordoh, José; Bianchini, Michele.

In: Molecular Cancer Therapeutics, Vol. 13, No. 5, 2014, p. 1369-1381.

Research output: Contribution to journalArticle

Arriaga, Juan M. ; Greco, Angela ; Mordoh, José ; Bianchini, Michele. / Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 5. pp. 1369-1381.
@article{695084adced44f0685a7c61df92df006,
title = "Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy",
abstract = "Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kB activity. Despite being silenced, MTs can be reinduced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate. In fact, this induction contributes to the cytotoxicity of these agents, given that silencing of MTs by siRNAs reduces their growth-inhibitory activities. Zinc ions also potently enhanceMT expression and are cytotoxic to cancer cells. We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kB. Addition of zinc enhanced growth inhibition by OXA and 5- FU, and was also capable of resensitizing 5-FU-resistant cell lines to levels comparable with sensitive cell lines. This effect wasMTindependent because silencing MTs did not affect zinc cytotoxicity. In conclusion, we show that MT induction and zinc administration are novel strategies to sensitize colorectal cancer cells to presently utilized chemotherapeutic agents.",
author = "Arriaga, {Juan M.} and Angela Greco and Jos{\'e} Mordoh and Michele Bianchini",
year = "2014",
doi = "10.1158/1535-7163.MCT-13-0944",
language = "English",
volume = "13",
pages = "1369--1381",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy

AU - Arriaga, Juan M.

AU - Greco, Angela

AU - Mordoh, José

AU - Bianchini, Michele

PY - 2014

Y1 - 2014

N2 - Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kB activity. Despite being silenced, MTs can be reinduced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate. In fact, this induction contributes to the cytotoxicity of these agents, given that silencing of MTs by siRNAs reduces their growth-inhibitory activities. Zinc ions also potently enhanceMT expression and are cytotoxic to cancer cells. We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kB. Addition of zinc enhanced growth inhibition by OXA and 5- FU, and was also capable of resensitizing 5-FU-resistant cell lines to levels comparable with sensitive cell lines. This effect wasMTindependent because silencing MTs did not affect zinc cytotoxicity. In conclusion, we show that MT induction and zinc administration are novel strategies to sensitize colorectal cancer cells to presently utilized chemotherapeutic agents.

AB - Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-kB activity. Despite being silenced, MTs can be reinduced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate. In fact, this induction contributes to the cytotoxicity of these agents, given that silencing of MTs by siRNAs reduces their growth-inhibitory activities. Zinc ions also potently enhanceMT expression and are cytotoxic to cancer cells. We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-kB. Addition of zinc enhanced growth inhibition by OXA and 5- FU, and was also capable of resensitizing 5-FU-resistant cell lines to levels comparable with sensitive cell lines. This effect wasMTindependent because silencing MTs did not affect zinc cytotoxicity. In conclusion, we show that MT induction and zinc administration are novel strategies to sensitize colorectal cancer cells to presently utilized chemotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=84899800704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899800704&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0944

DO - 10.1158/1535-7163.MCT-13-0944

M3 - Article

C2 - 24634414

AN - SCOPUS:84899800704

VL - 13

SP - 1369

EP - 1381

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -